1,846 Shares in United Therapeutics Co. (NASDAQ:UTHR) Bought by Hanseatic Management Services Inc.

Hanseatic Management Services Inc. acquired a new stake in United Therapeutics Co. (NASDAQ:UTHR) during the third quarter, according to its most recent filing with the SEC. The firm acquired 1,846 shares of the biotechnology company’s stock, valued at approximately $662,000.

Other institutional investors also recently bought and sold shares of the company. ClariVest Asset Management LLC boosted its holdings in shares of United Therapeutics by 120.0% in the second quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 42 shares in the last quarter. V Square Quantitative Management LLC purchased a new stake in United Therapeutics in the 2nd quarter valued at approximately $30,000. Innealta Capital LLC purchased a new stake in United Therapeutics in the 2nd quarter valued at approximately $33,000. USA Financial Formulas acquired a new position in United Therapeutics during the 3rd quarter worth approximately $33,000. Finally, Values First Advisors Inc. purchased a new position in shares of United Therapeutics during the 3rd quarter worth approximately $90,000. 94.08% of the stock is owned by institutional investors and hedge funds.

United Therapeutics Stock Performance

UTHR stock opened at $397.49 on Thursday. The company has a 50 day moving average price of $357.42 and a two-hundred day moving average price of $320.37. The stock has a market capitalization of $17.75 billion, a P/E ratio of 17.46, a PEG ratio of 1.08 and a beta of 0.56. United Therapeutics Co. has a one year low of $208.62 and a one year high of $399.23.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, beating analysts’ consensus estimates of $6.16 by $0.23. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business had revenue of $748.90 million during the quarter, compared to the consensus estimate of $722.62 million. During the same quarter in the previous year, the business earned $5.38 earnings per share. The business’s revenue for the quarter was up 22.9% on a year-over-year basis. Research analysts forecast that United Therapeutics Co. will post 25.57 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Christopher Causey sold 510 shares of the firm’s stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $376.63, for a total value of $192,081.30. Following the sale, the director now directly owns 3,675 shares of the company’s stock, valued at approximately $1,384,115.25. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other United Therapeutics news, Director Christopher Causey sold 510 shares of the business’s stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $376.63, for a total transaction of $192,081.30. Following the completion of the sale, the director now owns 3,675 shares of the company’s stock, valued at approximately $1,384,115.25. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Michael Benkowitz sold 14,700 shares of the firm’s stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $374.46, for a total value of $5,504,562.00. Following the completion of the transaction, the chief operating officer now owns 2,577 shares in the company, valued at approximately $964,983.42. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 81,422 shares of company stock valued at $29,229,828 in the last 90 days. 11.90% of the stock is currently owned by insiders.

Analysts Set New Price Targets

UTHR has been the subject of several research analyst reports. Wells Fargo & Company increased their price objective on United Therapeutics from $350.00 to $380.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 20th. LADENBURG THALM/SH SH increased their price target on shares of United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a report on Thursday, October 31st. HC Wainwright boosted their price objective on shares of United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Argus upped their target price on shares of United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. Finally, The Goldman Sachs Group lifted their price target on shares of United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, two have given a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $370.86.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.